

# Abbott ID NOW 2019-nCoV Symptomatic Testing Program

An Introduction for Providers in Yukon (August 2021)



Fig 1



# Important Note

This presentation is not intended to replace the training or certification process for the ID NOW system, and does not provide a comprehensive overview of the system, its implementation, or its use in Yukon.





# For the Presentation

- Open your Abbott ID NOW box
- Have the machine, cartridges and swabs with you
- Get a feel for the machine and its components!




# Background

- Rapid diagnostic molecular test (<15 min)
- Detects 2019-nCoV viral RNA from a nares/NP/throat swab
  - Isothermal NAAT (RT-LAMP), target genes: E and N2.
- Approved by Health Canada in October 2020
  - ‘Open ended’ direction to Provinces & Territories
- Single use cartridges and small footprint

Fig 2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)



© Encyclopædia Britannica, Inc.





# Background

- Intended for use in the first 7 days of symptom onset
  - Coincides with viral shedding
  - Also has applications for asymptomatic screening
- Results approach that of a PCR with Ct (cycle threshold) values <30
  - PCR is still 'gold standard'
  - PCR will detect early and late infections better
- Abbott data indicates ~95% sensitivity, 98% specificity
  - Data is early & variable, highly dependent on Ct values
  - Overall, literature suggests 77-80% sensitivity




Fig 3




Fig 4



# Sensitivity vs. Other Considerations

- Fast turnaround time
- Relatively low cost per test
- Increased testing frequency
- Multiple test settings
- Additional layer, 'bridging the gap'




Fig 5



# What's in the Box?



- \*Not pictured:
- Positive Quality Control Swab (silver packet)
- Barcode scanner




Fig 6



# ID NOW Cartridges


Fig 7

- **Test Bases:** Orange plastic components containing two reaction tubes of freeze-dried reagents for the targeted amplification of SARS-CoV-2 viral RNA and an internal control.
- **Sample Receivers:** Blue plastic components containing 2.5 mL of elution solvent.
- **Transfer Cartridges:** White plastic components used to transfer 2 x 100 µL (microliters) of sample extract from the Sample Receiver to the Test Base





# How to Test





# Testing Considerations

- Swabs must not be placed in transport media
  - ‘Dry’ swab should be eluted directly in to sample receiver
- If part of symptomatic testing, clients should be within 7 days of symptom onset
  - Otherwise follow routine processes
- Timing ‘post contact’ consideration
  - Strong likelihood of negative 1-3 days after exposure (~99%)
  - Slight improvement on day 4 (~67%)





# Testing Considerations, Cont.

- Results are considered preliminary
  - Confirmatory testing requirement in some cases
- Reduce interfering substances
  - If client has lots of mucous, blow nose before test



# Result Interpretation

## Positive:

- Considered 'preliminary' and must be confirmed via PCR
- Initiate isolation per routine process as the client is managed clinically as a positive case

## Negative:

- Interpret within clinical context and pre-test probability
- Confirm with PCR if strong clinical suspicion of COVID-19
- Continue to isolate if symptomatic or advised to for public health reasons
  - Retest in 2-3 days if symptoms persist

## Invalid:

- May repeat the test once using ID NOW **or** use a PCR
- x2 invalid results must be confirmed via PCR



Fig 8







# Applications and Considerations

- Useful in settings where rapid turnaround is critical
- Rural or remote settings with long transit times
- Can be used to *support* decision making and public health response in the interim





# Applications – Congregate Settings

- Entry upon entry/admission
- Serial testing
- Screening Programs





# Applications - Outbreaks

- Testing symptomatic individuals and contacts may allow for early identification
- Expedited case identification and contact tracing
  - Timing ‘post contact’ needs to be a consideration
- Reduced attrition or cases lost to follow-up





# Getting Started – New Sites

- Training new users & Certification
- Important Documents
- Clinic setup
- Instrument setup & standards
- Clinical Validation
- Quality Control
- Result reporting



# Training New Users & Certification

- Outlined process and steps to become certified
  - Detailed in training document
- Training session
- Training videos (NML, Abbott)
- Important documents
- Hands-on practice (quality control)
- Training quizzes and certificate
- Certification provided to YCDC and your supervisor



## ID NOW™ Training Certificate

FLU A/B 2\_\_\_\_ Strep A 2\_\_\_\_ RSV\_\_\_\_ COVID-19\_\_\_\_ (Check all that apply)

### SYSTEM OVERVIEW

- ☐ User manual
- ☐ Serial number location
- ☐ Package Insert (PI)

### SET-UP AND CONFIGURATION

- ☐ Instrument cleaning/maintenance
- ☐ Menu settings
- ☐ Date & time requirements

### SELF-TEST

- ☐ Review functions of test
- ☐ Frequency of test

### QUALITY CONTROL

- ☐ Storage & handling of control material
- ☐ Frequency of QC testing
- ☐ Logging results

### TEST SAMPLE PROCEDURE

- ☐ Storage & handling of test material
- ☐ Sample requirements & storage
- ☐ Sample collection
- ☐ Running a test

### TROUBLESHOOTING

- ☐ User manual
- ☐ Abbott product support: 800-257-9525

PRINT NAME OF TRAINER

SIGNATURE OF TRAINER

DATE

PRINT NAME OF TRAINEE

SIGNATURE OF TRAINEE

DATE

NAME OF INSTITUTION/FACILITY

FOR EXTERNAL USE. PRINT AND DISTRIBUTION PERMITTED.

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.



# Training and Best Practices



Abbott ID NOW  
Training Procedure for Symptomatic Testing  
August 20, 2021

## Abbott ID NOW – Training Procedure for Symptomatic Testing

### Table of Contents

1.0 Training Goals .....	7
2.0 Steps to Certification .....	8
3.0 Training Videos .....	8
4.0 Yukon Clinical Procedure .....	8
5.0 Personal Protective Equipment (PPE) .....	8
6.0 Specimen Collection and Handling .....	9
7.0 Hands-on Demonstrations .....	9
8.0 Checklists, Quizzes and Certification .....	9
9.0 Machine Set-up .....	9
9.1 Date and Time .....	10
9.2 Assay Preferences .....	10
9.3 Patient Details .....	10
9.4 Quality Control (QC) Lockout .....	10
9.5 Auto Print .....	10
9.6 Adding a New User .....	10
10.0 Quality Control and Clinical Validation .....	10
10.1 Quality Control .....	11
10.2 Clinical Validation .....	11
11.0 ID NOW Performance Best Practices – Quick Reference Guide .....	11
11.1 Lab safety and Disinfection .....	12
11.2 Proper Sample Collection .....	12
11.3 Correct Patient Identification .....	12
11.4 Proper Test Procedure .....	12
11.5 Transfer and Dispense .....	12

- Outlines training steps and certification process
- Setting up a new machine
- Best practices quick reference guide



# Clinical Procedure



Abbott ID NOW COVID-19 Test –Clinical Procedure  
for Symptomatic Testing-Policy and Procedure  
Date Effective: June 24, 2021

## ABBOTT ID NOW COVID-19 TEST - CLINICAL PROCEDURE FOR SYMPTOMATIC TESTING

### Table of Contents

1. Purpose .....	3
2. Principles .....	3
3. Roles and Responsibilities .....	4
2.10 Point of Care User .....	4
2.11 Super User .....	4
3. Specimen Information .....	5
4. Equipment and Supplies / Reagents / Forms and Labels .....	5
5. Safety Precautions .....	6
6. Quality Control .....	7
8. Equipment Maintenance .....	8
9. ID NOW Assessment Form (Appendix H) .....	8
10. Considerations for Clinic Setup .....	8
11. Instrument Start Up .....	8
12. Specimen Collection – Nasal swab .....	10
13. ID NOW Instrument .....	11
14. Interpretation of Results and Expected Values .....	13
15. Confirmatory Testing .....	14
16. Result Reporting .....	14
17. Method Limitations .....	14
18. Materials Management .....	15
19. Procedure Management .....	15
20. Applicability .....	15
21. References .....	15
22. Supporting Documents .....	15

- Detailed background information on Abbott ID NOW in YT
- Procedural information
- Materials management and ordering
- Support information
- Instrument forms





Peel and stick addressograph here

### Abbott ID NOW COVID-19 POCT Assessment Form for COVID-19- Symptomatic testing

Testing Date (YYYY/MM/DD)	Testing Location	Testing Provider
Last Name	First Name	DOB (YYYY/MM/DD)
Health Card #	Primary Phone	Alternate Phone
Physical Address		

Exposure Risks (Travel, Employment, Contacts, etc.)

Relevant PMHx, Medications, Psychosocial Hx.

#### Symptoms

<input type="checkbox"/> Fever / Chills	Temperature (°C) _____	<input type="checkbox"/> Fatigue
<input type="checkbox"/> Cough		<input type="checkbox"/> Anorexia
<input type="checkbox"/> SOB		<input type="checkbox"/> Nausea / Vomiting
<input type="checkbox"/> Dysgeusia / Anosmia		<input type="checkbox"/> Diarrhea
<input type="checkbox"/> Chest pain / tightness		<input type="checkbox"/> Myalgias
<input type="checkbox"/> Runny nose		<input type="checkbox"/> Dizziness / Confusion
<input type="checkbox"/> Sore throat		<input type="checkbox"/> Abdominal pain
<input type="checkbox"/> Headache		<input type="checkbox"/> Dermatological changes _____
<input type="checkbox"/> Conjunctivitis		<input type="checkbox"/> Other _____

Onset (YYYY/MM/DD) \_\_\_\_\_

#### Result

☐ Positive ☐ Negative ☐ Invalid (x1 or x2)

PCR sent? ☐ Yes (include requisition) ☐ No

If yes: ☐ Nasopharyngeal ☐ Saline Gargle

(For positives, two invalids, initial validation, q10 validation)

#### Plan

☐ Self-isolating, education done ☐ Isolation support contacted at  
and contact #s sheet given (867) 332-4587

☐ Phone call to YCDC / CMOH

☐ Other follow-up \_\_\_\_\_

Peel and stick result here

When complete, fax or email to Yukon Communicable Disease Control at (867) 667-8349 or  
YCDCsurveillance@yukon.ca

Effective: 2021-06-23

# Assessment Form

- Demographics section
- Risk and history section
- Symptom section
- Result section
  - Confirmatory section
- Plan section







# Instrument Setup and Standards

- All machines have an ‘admin’ login
  - Used to change settings and add users
- Follow the YG guide for machine setup/preferences to ensure consistency among test sites
- Each used must have a unique login (use YNET username)





# Clinical Validation

- Essential to verify the instrument across different settings and populations
- First 10 tests per machine will be validated with PCR testing
- Every 10<sup>th</sup> test will be validated with PCR testing
- NP or Saline Gargle



# Quality Control

- Machines must be QCd (+ & -):
  - With new user training
  - New cartridge LOT#
  - When the instrument is moved
  - Weekly, otherwise
- Must be logged in machine binder





# Results Reporting Standards

- Positives should be emailed/faxed ASAP to YCDC
- Negatives can be batched and sent at the end of the day
- Ensure patient and provider information is entered in the ID NOW **and** on the paper copy
- Fill out forms completely, store according to unit policy



# Supply Reporting

- Funding for the machines and cartridges is provided Federally
- Yukon is accountable for the tracking and use of supplies and cartridges
- Log your cartridges weekly for reporting purposes!



# Have Questions?

- Questions related to the *application/use in the Yukon*
  - Call YCDC at (867) 667-8323
  - Email [ycdcsurveillance@yukon.ca](mailto:ycdcsurveillance@yukon.ca)
- Technical questions:
  - Call Abbott Technical Support at 1-800-818-8335
  - Email [canproductsupport@abbott.com](mailto:canproductsupport@abbott.com)



# References

Abbott Laboratories. (n.d.). ID NOW™ Training Videos. Global Point of Care. <https://www.globalpointofcare.abbott/en/support/product-installation-training/id-now-training-videos.html>

Alberta Health Services. (2020, November 6). COVID-19 Scientific Advisory Group Rapid Evidence Report. [www.albertahealthservices.ca/assets/info/fpif-ppih-covid-19-sag-performance-and-feasibility-of-rapid-covid-19-tests-rapid-review.pdf&usg=AOvVaw24IFz8Ezno3gEH6u78h3fv](http://www.albertahealthservices.ca/assets/info/fpif-ppih-covid-19-sag-performance-and-feasibility-of-rapid-covid-19-tests-rapid-review.pdf&usg=AOvVaw24IFz8Ezno3gEH6u78h3fv)

Canadian Public Health Laboratory Network and the Canadian Society of Clinical Chemists. Interim guidance on the use of the Abbott ID NOW™ instrument and COVID-19 assay. Can Commun Dis Rep 2020;46(11/12):422–6. <https://doi.org/10.14745/ccdr.v46i1112a09>

Canadian Public Health Laboratory Network Laboratory Directors Council and the Canadian Public Health Laboratory Network Respiratory Virus Infection Working Group. Interim guidance on the use of the Abbott Panbio™ COVID-19 Antigen Rapid Test. Can Commun Dis Rep 2021;47(1):17–22. <https://doi.org/10.14745/ccdr.v47i01a04>

CMAJ 2021 March 29;193:E449-52. doi: 10.1503/cmaj.210100; early-released March 3, 2021

Saskatchewan Health Authority. (2021, January). Laboratory Clinical Procedure Abbott: ID Now COVID-19 Test. <https://www.saskhealthauthority.ca/news/service-alerts-emergency-events/covid-19/testing-screening-treatment-medical-directives/Documents/Testing/Abbott%2520ID%2520NOW%2520Device/PROV-46-Abbott-ID-NOW-COVID-19-Test-Clinical-Procedure.pdf+&cd=1&hl=en&ct=clnk&gl=ca&client=firefox-b-ab>





# Images used

- Fig 1: [https://www.selectscience.net/images/products/7468\\_ID-NOW-RSV.jpg.ashx?width=250&height=250&bgcolor=white](https://www.selectscience.net/images/products/7468_ID-NOW-RSV.jpg.ashx?width=250&height=250&bgcolor=white)
- Fig 2: <https://cdn.britannica.com/47/215947-050-66A6BF8B/Severe-acute-respiratory-syndrome-Coronavirus-SARS-CoV-2-COVID-19.jpg>
- Fig 3: [https://www.eppo.int/media/uploaded\\_images/MEETINGS/Meetings\\_2013/graphic.jpg](https://www.eppo.int/media/uploaded_images/MEETINGS/Meetings_2013/graphic.jpg)
- Fig 4: <https://static01.nyt.com/images/2020/10/02/us/charting-a-coronavirus-infection-promo-1601682548787/charting-a-coronavirus-infection-promo-1601682548787-superJumbo-v2.png>
- Fig 5: <https://i1.wp.com/emcrit.org/wp-content/uploads/2017/06/11image.png?resize=500%2C244>
- Fig 6: [https://www.rapidmicrobiology.com/rmbdata/userfiles/suppliers/abbott\\_laboratories/news/2019\\_ID\\_NOW.jpg](https://www.rapidmicrobiology.com/rmbdata/userfiles/suppliers/abbott_laboratories/news/2019_ID_NOW.jpg)
- Fig 7: <https://www.fishersci.com/shop/products/alere-i-flu-a-b-2-mod-24t-pk/23046634>
- Fig 8: [https://assets.fishersci.com/TFS-Assets/CCG/Abbott-Laboratories/product-images/Abbott%20Universal%20Printer\\_L-1%20Clipped%20051719%20\(002\)%20\(005\).jpg-650.jpg](https://assets.fishersci.com/TFS-Assets/CCG/Abbott-Laboratories/product-images/Abbott%20Universal%20Printer_L-1%20Clipped%20051719%20(002)%20(005).jpg-650.jpg)